HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Rose Sheet

Executive Summary

Colgate Q1: Colgate Luminous and Max Fresh helped drive U.S. toothpaste sales in the first quarter, firm says during April 26 earnings call. Colgate U.S. toothpaste market share rose 30 basis points to 36.5% year to date, company notes, citing ACNielsen data. North American sales grew 1.5% on a reported basis to $617.6 mil. and operating profit in the region declined 3% to $132.3 mil., primarily due to divestment of North American detergents business and increased ad spending, Colgate says. Net sales grew 4.5% on a reported basis to $2.87 bil. and net income was up 8% to $324.5 mil., including restructuring and stock compensation charges. Responding to an analyst question regarding the firm's interest in acquiring Pfizer's Listerine brand, CEO Reuben Mark said "it is in process, and I guess Pfizer or Pfizer's investment banking people will tell you that. There is an orderly process and...we're at stage X, [but] stage Y will be coming up." Pfizer recently announced it would consider selling its consumer unit, but noted it had no plans to divest individual brands (1"The Rose Sheet" Feb. 13, 2006, p. 7)...
Advertisement

Related Content

Kanebo Sensai Anti-Aging Skin Care Extends Into Foundations
Kanebo Sensai Anti-Aging Skin Care Extends Into Foundations
Pfizer Values Standalone Consumer Unit At $10 Bil.
Pfizer Values Standalone Consumer Unit At $10 Bil.
Advertisement
UsernamePublicRestriction

Register

RS013910

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel